Global Leukemia Therapeutics Market – By Disease Type (Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia, and Acute Myeloid Leukemia), By Drug Class (Small Molecules and Biologics), and By Regions (North America, Europe, Asia Pacific, and Rest of the World): Forecast up to 2025

Global Leukemia Therapeutics Market – By Disease Type (Chronic Myeloid

Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia, and

Acute Myeloid Leukemia), By Drug Class (Small Molecules and Biologics), and By

Regions (North America, Europe, Asia Pacific, and Rest of the World): Forecast up

to 2025

This market research report includes a detailed segmentation of the global

leukemia therapeutics market by disease type (chronic myeloid leukemia, chronic

lymphocytic leukemia, acute lymphocytic leukemia, and acute myeloid leukemia), by

drug class (small molecule and biologics), and by regions (North America, Europe,

Asia Pacific, and Rest of the World).

Overview of the Global Leukemia Therapeutics Market Research:

IHR Insights’s market research report predicts that the global leukemia therapeutics

market will grow at a CAGR of 6.2% during the forecast period 2019–2025. Leukemia

refers to the group of blood cancer that usually develops in the bone marrow,

resulting in the formation of abnormal blood cells. Leukemia is subdivided into

lymphoblastic or lymphocytic leukemias and myeloid or myelogenous leukemias

that include acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL),

chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML).

The upsurge in the incidence of leukemia cases across the globe, rising elderly

population, and the advent of innovative therapies are among the factors driving

the market growth. In the US, an estimated 61,780 people were expected to be

diagnosed with leukemia in 2019. Approximately 10,670 people died of AML in 2018.

In Europe, nearly 30,000 people had CLL in 2018. Leukemia was the 8th most

commonly diagnosed cancer in Australia with 3,905 cases in 2015 and it is estimated

that leukemia will remain the 8th most commonly diagnosed cancer in 2019.

However, strict regulatory guidelines, increased cost of the drug, and side effects

associated with drugs are few of the factors that may prove detrimental to the

market. Growing investment in R&D for the development of the new drugs,

promising pipeline, and opportunities in emerging economies are anticipated to

enhance the revenue of the leukemia therapeutics market in the next five years.

•Promisingpipelineofleukemiadrugs•OpportunitiesinemergingeconomiesOpportunities

Risk•Highcostofthedrugs•Strictregulatoryguidelines

Drivers•Increasing incidence of leukemia cases across the globe•Rising elderly population

Market dynamics

Thekeymarketplayersuseproductapprovalasoneofthekeystrategiestostrengthentheirpositioninthemarket.Forinstance,inApril2018,PfizerInc.receivedEuropeanCommissionapprovalforMYLOTARGincombinationwithdaunorubicinandcytarabine,whichisthefirstandonlyAMLtherapyapprovedintheEUthattargetsCD33.CAGR of 6.2%: 2019–2025

CAGR >7.5%

The industry generates the majority of the revenue from the key players operating

in this field; few of them include Novartis AG, F-Hoffmann-La Roche Ltd., Pfizer Inc.,

Sanofi S.A., Bristol–Myers Squibb Company, and AbbVie Inc.

According to the IHR Insights analysis, North America accounted for the

largest share of the global leukemia therapeutics market in 2018 and will retain a

high position during the forecast period. North America is followed by Europe with a

share of more than 25% of the global market in 2018.

By Disease Type:

 Chronic Myeloid Leukemia (CML)

 Chronic Lymphocytic Leukemia (CLL)

 Acute Lymphocytic Leukemia (ALL)

 Acute Myeloid Leukemia (AML)

In 2018, the chronic myeloid leukemia segment accounted for the largest share and

is expected to grow at a mid-single-digit CAGR by 2025. The high prevalence rate of

CML and the availability of a huge number of treatment choices make the segment

the largest shareholder in the global leukemia therapeutics market.

By Molecule Type:

 Small Molecules

 Biologics

Based on the molecule type analysis, the small molecules segment dominated the

market in 2018 with a share of over 75% and is expected to maintain this position

throughout the forecast period. Biologics is expected to grow at a high CAGR during

the forecast period 2019–2025.

By Regions:

 North America

 Europe

 Asia Pacific

 Rest of the World

Based on geography, North America dominated the market in 2018 with a share of

over 40% and is expected to grow at mid-single-digit CAGR during the forecast

period 2019–2025. The high incidence and prevalence rate of the disease, increasing

awareness on personalized medicine, and the existence of reputed players

extensively involved in the commercialization of branded therapeutics make the

region a dominant shareholder in the global leukemia therapeutics market. Asia

Pacific is projected to grow at a high CAGR during the forecast period 2019–2025.

Global Leukemia Therapeutics Market Research Competitive Analysis: The

market is growing at a steady rate with a CAGR of 6.2% during the forecast period

2019–2025. There are many new drug launches, approval, development, and

funding related to leukemia drugs owing to the increased patient base across the

globe. For instance, in 2019, Ivosidenib (TIBSOVO) developed by Agios

Pharmaceuticals, Inc. was approved by the FDA for the treatment of AML in older

patients with a susceptible IDH1 mutation who have comorbidities that preclude the

use of intensive induction chemotherapy. Astellas Pharma received FDA approval

for gilteritinib, in November 2018, the first-ever inhibitor drug explicitly approved for

treating patients with relapsed or refractory AML with a mutation in the FLT3 gene.

FDA granted a supplemental approval to acalabrutinib (Calquence) developed by

AstraZeneca to treat CLL or SLL in December 2019.

There is an increasing collaboration to develop novel leukemia therapeutics. For

instance, MD Anderson Cancer Center and Ascentage Pharma entered into a five-

year collaboration that aims to accelerate clinical development of novel apoptosis-

targeted and tyrosine kinase inhibitor drug candidates for leukemia treatment.

Key Vendors:

 Novartis AG

 F-Hoffmann-La Roche Ltd.

 Pfizer Inc.

 Sanofi S.A.

 Bristol–Myers Squibb Company

 AbbVie Inc.

 Amgen Inc.

 Takeda Pharmaceutical Company Limited

 Gilead Science Inc.

 GlaxoSmithKline

 Eisai Co. Ltd.

 Biogen Inc.

Key Competitive Facts:

 The pipeline of oncology drugs in the clinical development has expanded by

45% over the past 10 years; 87% of the late-stage pipeline is targeted

therapies, which include small molecule protein kinase inhibitors and biologic

monoclonal antibodies.

 Jazz Pharmaceuticals plc received European Commission approval for its

marketing authorization application for Vyxeos in August 2018 for the

treatment of newly diagnosed AML with myelodysplasia-related changes in

adult patients or therapy-related acute myeloid leukemia.

Benefits – The report provides complete details about the sub-segment of the

global leukemia therapeutics market. Thus, the key stakeholders can know about

the major trends, drivers, investments, vertical player’s initiatives, and government

initiatives toward the pharmaceutical segment in the upcoming years, along with

details of the pureplay companies entering the market. Moreover, the report

provides details about the major challenges that are going to impact the market

growth. Additionally, the report gives complete details about the key business

opportunities to key stakeholders in order to expand their business and capture the

revenue in specific verticals, and to analyze before investing or expanding the

business in this market.

Key Takeaways:

 Understanding the potential market opportunity with precise market size and

forecast data.

 Detailed market analysis focusing on the growth of the leukemia therapeutics

industry.

 Factors influencing the growth of the leukemia therapeutics market.

 In-depth competitive analysis of dominant and pure-play vendors.

 Prediction analysis of the leukemia therapeutics industry in both developed

and developing regions.

 Key insights related to major segments of the leukemia therapeutics market.

 Latest market trend analysis impacting the buying